Temozolomide (NCT07085338)

Name: Temozolomide trial for Neuroblastoma Recurrent (NCT07085338)
Uploaded: 2026-10-31T20:16:15.671Z
Duration: 1 min 23 s
Description: Temozolomide trial for Neuroblastoma Recurrent (NCT07085338). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07085338.

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma: a one-minute explainerNCT070853381 min

Temozolomide trial for Neuroblastoma Recurrent (NCT07085338). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people under thirty with high-risk neuroblastoma that returned, progressed, or persisted after treatment. Refractory or persistent disease requires at least four induction cycles.

The idea: N-803 activates natural killer cells and T cells. After a safety run-in, patients are randomized to irinotecan, temozolomide, hu14.18K322A, and GM-CSF with or without N-803. The added drug is injected under the skin on day six of each three-week cycle. Researchers compare responses and toxicity.

This phase 2 study plans 54 patients. Sara Federico leads at St. Jude in Memphis; two US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.